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Abstract
A number of studies have shown that increased APP levels, resulting from either a genomic locus
duplication or alteration in APP regulatory sequences, can lead to development of early-onset
dementias, including Alzheimer's disease (AD). Therefore, understanding how APP levels are
regulated could provide valuable insight into the genetic basis of AD and illuminate novel
therapeutic avenues for AD. Here we test the hypothesis that APP protein levels can be regulated
by miRNAs, evolutionarily conserved small noncoding RNA molecules that play an important role
in regulating gene expression. Utilizing human cell lines, we demonstrate that miRNAs hsa-mir-
106a and hsa-mir-520c bind to their predicted target sequences in the APP 3'UTR and negatively
regulate reporter gene expression. Over-expression of these miRNAs, but not control miRNAs,
results in translational repression of APP mRNA and significantly reduces APP protein levels. These
results are the first to demonstrate that levels of human APP can be regulated by miRNAs.
Results
Accumulating evidence suggests that increased expression
of the amyloid precursor protein gene (APP) increases
Alzheimer's disease (AD) risk. The resulting increase in
APP protein levels results in increased Aβ levels, leading to
synaptic dysfunction, neurodegeneration and, eventually,
cognitive decline.
APP levels can be regulated at the genomic, transcriptional
or translational level. At the genomic level, Down's Syn-
drome (Trisomy 21) patients have three copies of the APP
gene and develop AD symptoms early in life [1]. Similarly,
duplication of the APP locus, in the absence of a full tri-
somy 21, also leads to early-onset AD [2]. Dysregulation
of  APP  transcription can also increase the risk of AD.
Genetic variants in the APP promoter increase APP tran-
scription by ~2–3 fold and have been reported to increase
AD risk [3]. Growth factors have been reported to control
APP mRNA half-life [4]. These growth factors effects are
dependent on a 29 bp sequence in the APP 3' UTR [4,5].
APP translation is also regulated; for example, IL-1 can
induce an increase in APP translation [6]. IL-1 is a pro-
inflammatory cytokine and genetic variants have been
linked to increased AD risk [7,8]. Taken together, these
findings provide strong evidence that increased APP levels
increase AD risk.
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MicroRNAs (miRNAs) are small noncoding RNAs that
control gene expression post-transcriptionally. Comple-
mentary binding between miRNAs and sequences within
the 3' UTR of target genes results in repression of target
gene expression by translational inhibition or mRNA deg-
radation [9]. Approximately 700 miRNA genes are
encoded in the human genome and recent evidence dem-
onstrates that some miRNAs are differentially expressed in
AD patients compared to age-matched controls [10].
These differences in miRNA expression may play an
important role in AD pathogenesis. In an attempt to
address this possibility, we test the hypothesis that miR-
NAs can regulate APP levels.
Bioinformatic analysis predicts that the 3' UTR of human
APP contains 28 unique miRNA target sites [11,12]. To
experimentally confirm that APP levels can be regulated
by miRNAs, we chose to initially study miRNA hsa-mir-
106a (mir-106a; Figure 1A) since (i) the putative target
site in the APP 3'UTR is 100% complementary to the seed
region of the miRNA, (ii) it has a large free energy of seed
region binding, and (iii) it is expressed in human brain
[13]. To determine if the putative mir-106a target site in
the APP 3'UTR is capable of regulating gene expression,
we cloned it into the 3' UTR of firefly luciferase. We co-
transfected this reporter into naïve HEK-293 cells along
with a mir-106a over-expression vector [14] and meas-
ured luciferase activity (Figure 1B). We observed a signifi-
mir-106a target sequence regulates reporter gene expression Figure 1
mir-106a target sequence regulates reporter gene expression. (A) Predicted mir-106a and mir-520c target sites in 
the 3'UTR of APP. (B) Over-expression of mir-106a or mir-520c, but not mir-373, significantly reduced luciferase expression 
(p = 0.0006) controlled by the putative mir-106a APP 3'UTR target sequence. This reduction is not observed when a seed 
region mutant of mir-106a (106a*) is utilized. For all experiments, three independent trials were performed. Error bars repre-
sent standard deviation. *p < 0.05; **p < 0.01, compared to the appropriate control.
B.
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cant ~50% decrease (p < 0.0001) in luciferase activity
when the putative mir-106a target site was included in the
reporter compared to either a reporter lacking the putative
target site or reporter carrying a seed-region mutant of the
putative mir-106a target site. To determine if this effect
was simply due to over-expressing miRNAs, we repeated
the experiment while over-expressing mir-373, a miRNA
not predicted to target the APP 3'UTR. We observed no
change in luciferase activity. Another miRNA, mir-520c,
shares the same seed region target sequence as mir-106a
but is not expressed in human brain (Figure 1A) [13].
Therefore we tested mir-520c, we observed that mir-520c
over-expression significantly decreased luciferase activity
when the putative mir-106a target site was included in the
reporter compared to either a reporter lacking the putative
target site or a reporter carrying a seed-region mutant of
the putative mir-106a target site (Figure 1B). We repeated
these experiments in the human neuroblastoma cell line
SH-SY5Y and observed similar results (data not shown).
To confirm that the miRNAs were being over-expressed,
we utilized RT-QPCR to quantify miRNA levels and
observed significant increases in both mir106a and mir-
520c (Table 1) levels (p < 0.0001).
Having demonstrated that over-expression of mir-106a or
mir-520c was capable of repressing reporter gene expres-
sion via interaction with its putative target site, we inves-
tigated whether over-expression of these miRNAs could
decrease endogenous APP levels in human cell lines. We
transfected naïve HEK-293 with mir-106a and mir-125b
over-expression vectors and then performed quantitative
Western blot analysis to determine APP steady state levels.
We utilized mir-125b as a negative control since it is not
predicted to target APP but has increased expression in AD
brain [10]. We observed that mir-106a over-expression
significantly decreased APP levels (Figure 2A). Both APP
isoforms expressed in this cell line, APP770 and APP751,
were significantly and similarly affected. Mir-106a over-
expression reduced APP levels by ~50% (p < 0.01) com-
pared to cells transfected with the empty vector (Figure
2C). Over-expression of mir-125b had no significant
effect on APP levels. Over-expression of mir-520c had a
similar effect on APP levels as mir-106a (Figure 2B and
2D).
Most human miRNAs repress gene expression by inhibit-
ing translation and do not affect target gene mRNA levels
[15,16]. This seems to be the case in our experimental set-
ting. We utilized RT-QPCR to determine if miRNA over-
expression resulted in decreased APP mRNA levels. Over-
expression of mir-106a or mir-520c had no effect on APP
mRNA levels (Figure 2E). Mir-106a and mir-520c, there-
fore, appear to inhibit translation of the APP transcript.
Our results are the first to experimentally demonstrate
that human APP levels can be regulated by miRNAs. In
2004, it was predicted that APP levels could be regulated
by miRNAs [12]; recently it was shown that expression of
the C. elegans orthologue of APP, APL-1, is regulated by
developmentally-timed miRNAs [17].
In human neurons the APP695 isoform is the predominant
expressed isoform. All APP isoforms (APP695, APP751 and
APP770) share the same 3' UTR [18] therefore we expect
that the mir-106a mediated regulation of APP levels that
we observe in the HEK-293 cell line should also occur in
neurons given that mir-106a is expressed in the brain. We
do not expect mir-520c mediated APP regulation to occur
in neurons since this miRNA is not expressed in brain. It
is important to test if miRNA regulation is a normal aspect
of APP metabolism in neurons. If so, it will be important
to determine whether AD pathogenesis is affected by alter-
ations in miRNA function and/or expression. It is possible
that aging- or environment-induced changes in miRNA
expression, and/or sequence variation in miRNAs or their
targets, contribute to increased APP levels and increased
AD risk. Recently, it was demonstrated that expression of
the  β-secretase BACE can be regulated by miR-29a/b-1
and mir-107; furthermore, increased BACE levels corre-
lated with decreased miR-29a/b-1 and mir-107 levels in
AD patients [19,20].
Regardless of the biological roles of miRNA in APP metab-
olism, therapeutics based on miRNA-induced decrease in
APP levels would offer a treatment targeting the underly-
ing pathophysiology of the disease. In the near future,
substantial progress will be made in understanding the
role of miRNAs in AD pathogenesis and in therapeutic
approaches to treating AD.
Methods
Reporter Vectors and DNA constructs
Reporter vectors containing the putative miRNA target
sites from the APP 3'UTR, were synthesized with double-
stranded oligos perfectly complementary to putative
miRNA target sites and oligos in which the seed regions
were mutated. The mir-106a target oligos had the
sequence (seed region bolded):
Table 1: Relative miRNA levels
Fold Change 2-ΔΔCt p-value
Vector 1
mir-106a 30.1 ± 1.2 < 0.0001
mir-520c 1964.6 ± 1.1 < 0.0001
QPCR results demonstrate a significant increase in mir-106a and mir-
520c levels in response to over-expression compared to cells 
transfected with an empty vector.Molecular Neurodegeneration 2008, 3:10 http://www.molecularneurodegeneration.com/content/3/1/10
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5' CTAGTAATCCCTGTTCATTGTAAGCACTTTTGCT-
CAGCA 3'
3' ATTAGGGACAAGTAACATTCGTGAAAACGAGTCGT-
TCGA 5'
The mutant mir-106a target oligos had nucleotides three
through six of the seed region mutated (italicized):
5' CTAGTAATCCCTGTTCATTGTAAGCGTCCTTGCT-
CAGCA 3'
3' ATTAGGGACAAGTAACATTCGCAGGAACGAGTCGT-
TCGA 5'
We utilized established methods [21] to clone these syn-
thetic versions of putative miRNA target sites into a luci-
ferase reporter gene (pMIR-REPORT; Ambion).
Cells and Cell Culture
Naïve human embryonic kidney (HEK)-293 cells were
purchased from ATCC. Cells were cultured in Dulbecco's
modified Eagle's medium (DMEM) supplemented with
mir-106a and mir-520c can regulate APP levels post-transcriptionally Figure 2
mir-106a and mir-520c can regulate APP levels post-transcriptionally. APP770 and APP751 levels are reduced in cells 
over-expressing (A) mir-106a compared to cells expressing either mir-125b or the empty vector and (B) mir-520c compared 
to cells expressing the empty vector. (C) Quantification of these Western blot results reveals that mir-106a over-expression 
significantly decreases APP levels (p < 0.01) compared to cells expressing mir-125b or cells transfected with the empty vector. 
(D) Quantification of these Western blot results reveals that mir-520c over-expression significantly decreases APP levels (p < 
0.01) compared to cells transfected with the empty vector. (E) QPCR results show that APP mRNA levels are not altered by 
mir-106a or mir-520c over-expression. For all experiments, three independent trials were performed. Error bars represent 
standard deviation. *p < 0.05; **p < 0.01, compared to the appropriate control.
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10% fetal bovine serum, 2 mM L-glutamine,100 units/ml
penicillin and 100 μg/ml streptomycin.
Transfections and Luciferase Assays
10,000 Naïve HEK-293 were plated in 24 well plates. The
next day, cells were transfected with a miRNA overexpres-
sion vector [14], reporter vectors bearing either the
miRNA target sequence or the miRNA seed region mutant
target sequence, and one tenth of the molar volume of
pRL-SV40, a Renilla Luciferase control vector. We utilized
Arrest-In transfection reagent (Open Biosystems Inc.); any
differences in transfection efficiency were accounted for
by measuring Renilla luciferase activity. 48 hours post-
transfection, cell were lysed using 100 μL of GLB (Glo
Lysis Buffer, Promega). Firefly and Renilla luciferase activ-
ities were measured using a dual luciferase reporter assay
kit (Promega), per the manufacturer's protocol. Firefly
luciferase activity was normalized to Renilla luciferase
activity.
Western Blot Analysis
200,000 Naïve 293 cells were plated in 6 well plates. The
next day, cells were transfected with a miRNA overexpres-
sion vector. Using previously described methods [22],
quantitative Western blots were performed using equal
amounts of total protein.
Antibodies
A polyclonal antibody specific for the C-terminus of
human APP (A8717; Sigma Aldrich, Inc) and a mono-
clonal antibody specific for human β-Actin (A5441;
Sigma Aldrich) were used as primary antibodies. Second-
ary antibodies were HRP-conjugated goat anti-rabbit (GE
Healthcare) and HRP-conjugated goat anti-mouse (GE
Healthcare).
RNA extraction and Quantitative PCR
48 hours post-transfection, cells were washed with cold
PBS and total RNA was isolated using RNeasy Mini Kit
(Qiagen Inc.). To quantify APP mRNA levels, cDNA was
synthesized using total RNA, N6 random primers and
SuperScript II Reverse Transcriptase (Invitrogen). cDNA
was then diluted 1:15 using RNase free water and mixed
with APP or GAPDH primer/probe sets (Applied Biosys-
tems, Inc.; APP Catalog # Hs00169098_m1; GAPDH Cat-
alog # Hs99999905_m1), 2× PCR Universal Master Mix
(Applied Biosystems, Inc.) and amplified using an ABI
7500 Real Time PCR system following the manufacturer's
directions. GAPDH was used as an internal control. To
determine differences in APP mRNA levels, we utilized the
ΔΔCt method.
To quantify miRNA levels, cDNA was reverse transcribed
from total RNA samples using specific miRNA primers
from the TaqMan MicroRNA Assays and reagents from the
Taq Man MicroRNA Reverse Transcription kit (Applied
Biosystems). The resulting cDNA was amplified by PCR
using TaqMan MicroRNA Assay primers with the TaqMan
Universal PCR Master Mix and analyzed with a 7500 ABI
PRISM Sequence Detector System (Applied Biosystems)
according to the manufacturer's instructions. The relative
levels of miRNA expression were calculated from the rele-
vant signals by the ΔΔCt method by normalization to the
signal of RNU44 [23].
Statistical Analysis
Values in the text and figures are presented as means ±
standard deviations of experiments carried out in tripli-
cate, at least. Each experiment was carried three times.
Equal variance or separate variance two-sample student's
t-test were used, as appropriate, to compare two groups.
Where appropriate, Bonferroni analysis was used to cor-
rect for multiple comparisons within a single experiment.
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